LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lakewood-Amedex Biotherapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.58+0.00 (+0.59%)
Close on Oct 19, 2026
- Market cap
- $828.29K
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
7 of Lakewood-Amedex Biotherapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Sep 22, 2026 | Sep 29, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 14, 2026 | SEC EDGAR |
| Proxy statement | DEF 14A | Sep 22, 2026 | Aug 10, 2026 | SEC EDGAR |
| Current report | 8-K | Jul 15, 2026 | Jul 15, 2026 | SEC EDGAR |
| Current report | 8-K | Jun 15, 2026 | Jun 17, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 22, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 24, 2026 | Apr 28, 2026 | SEC EDGAR |